AU2018281617B2 - Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient - Google Patents

Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient Download PDF

Info

Publication number
AU2018281617B2
AU2018281617B2 AU2018281617A AU2018281617A AU2018281617B2 AU 2018281617 B2 AU2018281617 B2 AU 2018281617B2 AU 2018281617 A AU2018281617 A AU 2018281617A AU 2018281617 A AU2018281617 A AU 2018281617A AU 2018281617 B2 AU2018281617 B2 AU 2018281617B2
Authority
AU
Australia
Prior art keywords
gly
leu
ala
gln
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018281617A
Other languages
English (en)
Other versions
AU2018281617A1 (en
Inventor
Taegon Baik
Deuk-young GOO
Taek-Soo Kim
Dae-Seong Lim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuyu Pharma Inc
Original Assignee
Yuyu Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuyu Pharma Inc filed Critical Yuyu Pharma Inc
Publication of AU2018281617A1 publication Critical patent/AU2018281617A1/en
Application granted granted Critical
Publication of AU2018281617B2 publication Critical patent/AU2018281617B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018281617A 2017-05-17 2018-05-17 Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient Active AU2018281617B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170061250 2017-05-17
KR10-2017-0061250 2017-05-17
PCT/KR2018/005673 WO2018225961A1 (ko) 2017-05-17 2018-05-17 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
AU2018281617A1 AU2018281617A1 (en) 2019-12-05
AU2018281617B2 true AU2018281617B2 (en) 2022-06-30

Family

ID=64566301

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018281617A Active AU2018281617B2 (en) 2017-05-17 2018-05-17 Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient

Country Status (13)

Country Link
US (1) US12037415B2 (https=)
EP (1) EP3643723B1 (https=)
JP (2) JP7680824B2 (https=)
KR (2) KR102287226B1 (https=)
CN (1) CN110945012A (https=)
AU (1) AU2018281617B2 (https=)
BR (1) BR112019024040A2 (https=)
CA (1) CA3063842A1 (https=)
ES (1) ES2982308T3 (https=)
MX (1) MX2019013799A (https=)
RU (1) RU2766160C2 (https=)
SG (1) SG11201912110YA (https=)
WO (1) WO2018225961A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240228538A1 (en) * 2019-05-21 2024-07-11 Eyebio Korea Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102287226B1 (ko) 2017-05-17 2021-08-11 주식회사 유유제약 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
TWI865470B (zh) * 2018-11-14 2024-12-11 南韓商柳柳製藥股份有限公司 治療眼睛疾病之肽及醫藥組合物
KR20210104460A (ko) * 2020-02-17 2021-08-25 주식회사 아이바이오코리아 고체상 합성법을 이용한 펩타이드의 제조 방법
EP4114430A4 (en) * 2020-03-05 2025-05-14 YUYU Pharma, Inc. TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS
KR102593936B1 (ko) * 2021-12-13 2023-10-27 주식회사 아이바이오코리아 신규한 펩타이드를 포함하는 황반변성의 치료용 조성물
AU2022412618B2 (en) * 2021-12-13 2026-02-19 Eyebiokorea, Inc. Composition for treating macular degeneration comprising novel peptide
KR102587729B1 (ko) * 2023-02-27 2023-10-12 주식회사 아이바이오코리아 펩타이드를 포함하는 당뇨망막병증의 치료용 조성물
KR102673860B1 (ko) * 2023-08-10 2024-06-12 (주)케어젠 안구 건조증의 개선 활성을 갖는 펩타이드 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO2017018613A1 (ko) * 2015-07-30 2017-02-02 인제대학교 산학협력단 건성안 예방 또는 치료용 약학조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117444A2 (en) * 2006-03-31 2007-10-18 Yinghe Hu Protein detection by aptamers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
JP4490498B2 (ja) 2008-09-30 2010-06-23 新田ゼラチン株式会社 疾病抑制剤
CA2836946C (en) * 2011-05-27 2017-08-01 Allergan, Inc. A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
MX2014006399A (es) * 2011-11-30 2015-04-10 Xigen Inflammation Ltd Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca.
KR101438744B1 (ko) * 2012-08-02 2014-09-15 전남대학교산학협력단 아디포넥틴을 유효성분으로 포함하는 안구건조증 또는 염증성 안구표면 질환의 예방 또는 치료용 조성물
KR101555296B1 (ko) 2013-12-10 2015-09-23 인제대학교 산학협력단 연골세포 유래 세포외 기질을 유효성분으로 함유하는 건성안 예방 또는 치료용 약학조성물
KR101948156B1 (ko) 2013-12-10 2019-02-14 인제대학교 산학협력단 알칼리 화상을 이용한 각막 혼탁증 동물모델 및 각막 혼탁증 예방 또는 치료용 약학조성물
KR101721059B1 (ko) 2014-12-26 2017-03-30 주식회사 아이바이오코리아 안구 표면 질환 예방 또는 치료용 약학조성물
TWI675851B (zh) 2015-12-14 2019-11-01 台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院 短合成胜肽及其用途
CN109310731B (zh) * 2016-04-08 2022-03-29 韩国视角生物株式会社 软骨细胞的细胞外基质来源的肽
KR101798183B1 (ko) * 2016-04-08 2017-11-15 주식회사 아이바이오코리아 건성안 예방 또는 치료용 약학조성물
KR101795653B1 (ko) 2016-05-19 2017-11-09 인제대학교 산학협력단 콜라겐 타입 ii 펩타이드-아플리버셉트의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
KR20180074928A (ko) 2016-12-26 2018-07-04 주식회사 아이바이오코리아 건성안 예방 또는 치료용 동물 의약품 조성물
KR102287226B1 (ko) 2017-05-17 2021-08-11 주식회사 유유제약 신규한 펩타이드 및 이를 유효성분으로 포함하는 안구질환 치료용 약학 조성물
TWI865470B (zh) * 2018-11-14 2024-12-11 南韓商柳柳製藥股份有限公司 治療眼睛疾病之肽及醫藥組合物
US11613558B2 (en) 2018-11-14 2023-03-28 Yuyu Pharma, Inc. Peptides and pharmaceutical compositions for treating eye diseases
EP4114430A4 (en) * 2020-03-05 2025-05-14 YUYU Pharma, Inc. TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
WO2017018613A1 (ko) * 2015-07-30 2017-02-02 인제대학교 산학협력단 건성안 예방 또는 치료용 약학조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHAE EUN KIM ET AL, "Effects of chondrocyte-derived extracellular matrix in a dry eye mouse model", MOLECULAR VISION, (2015-10-26), vol. 21, pages 1210 - 1223 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240228538A1 (en) * 2019-05-21 2024-07-11 Eyebio Korea Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof
US12428446B2 (en) * 2019-05-21 2025-09-30 Eyebio Korea Peptide compound or pharmaceutically acceptable salt thereof

Also Published As

Publication number Publication date
SG11201912110YA (en) 2020-01-30
EP3643723B1 (en) 2024-05-15
RU2019141646A3 (https=) 2021-07-28
ES2982308T3 (es) 2024-10-15
JP2023098936A (ja) 2023-07-11
RU2019141646A (ru) 2021-06-17
JP2020520372A (ja) 2020-07-09
CN110945012A (zh) 2020-03-31
US12037415B2 (en) 2024-07-16
BR112019024040A2 (pt) 2020-09-24
US20210024577A1 (en) 2021-01-28
RU2766160C2 (ru) 2022-02-08
EP3643723C0 (en) 2024-05-15
MX2019013799A (es) 2020-08-13
KR102498428B1 (ko) 2023-02-20
EP3643723A1 (en) 2020-04-29
CA3063842A1 (en) 2019-12-09
AU2018281617A1 (en) 2019-12-05
KR20210097670A (ko) 2021-08-09
EP3643723A4 (en) 2021-03-31
WO2018225961A1 (ko) 2018-12-13
KR102287226B1 (ko) 2021-08-11
KR20180126406A (ko) 2018-11-27
JP7775250B2 (ja) 2025-11-25
JP7680824B2 (ja) 2025-05-21

Similar Documents

Publication Publication Date Title
AU2018281617B2 (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
AU2022201488A1 (en) Compositions and methods for treating EZH2-mediated cancer
AU2019378162B2 (en) Peptides and pharmaceutical compositions for treating eye diseases
WO2022021841A1 (zh) 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途
CA2746264A1 (en) New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
WO2021191689A2 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
WO2023056936A1 (zh) 一种核苷酸衍生物及其药物组合物和用途
CN110028508A (zh) 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂
CA3119921C (en) Peptides and pharmaceutical compositions for treating eye diseases
RU2819399C2 (ru) Пептиды и фармацевтические композиции для лечения глазных болезней
HK40017864A (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
CN113773273B (zh) 苯并异噻唑类化合物及其制备方法和用途
CN111868022A (zh) 以锌结合剂为基础的ebna1特异性化合物
HK40061089A (en) Peptides and pharmaceutical compositions for treating eye diseases
HK40061089B (zh) 用於治疗眼病的肽和药物组合物
WO2025103192A1 (zh) 一种氘代喜树碱化合物及其制备和应用
HK40037057A (en) Zinc-binder based ebna1-specific compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)